Covid-19 roundup: As­traZeneca pub­lish­es da­ta on blood clots as­so­ci­at­ed with vac­cine; Glax­o­SmithK­line and Vir ink mAb ...

4 years ago
Coronavirus

Glax­o­SmithK­line punts a key Ze­ju­la com­bo study in ovar­i­an can­cer with added set­backs on ICOS and RSV

4 years ago
R&D

NewAms­ter­dam Phar­ma res­ur­rects Am­gen's old CETP drug with plans to jump in­to PhI­II this year

4 years ago
R&D

In halt­ing con­fir­ma­to­ry tri­al for On­copep­tides' ac­cel­er­at­ed ap­proval, FDA notes in­creased risk of death

4 years ago
FDA+

One Ring to rule them all? Flag­ship’s big bet on dom­i­nat­ing gene ther­a­py 2.0 at­tracts a $117M megaround

4 years ago
R&D

Bio­gen push­es for broad CMS cov­er­age of Alzheimer's drug — while Eli Lil­ly looks to es­cape an NCD

4 years ago
Pharma

Deer­field and ARCH back a new $200M SPAC run by Cal­i­for­nia VC firm

4 years ago
Financing

As­traZeneca castoff draws $123M wa­ger on CX­CR2 an­tag­o­nist as Are­na lines up a buy­out op­tion

4 years ago
Financing
Deals

Deep Ge­nomics, now flush with cash, plans to take dozens of RNA ther­a­pies to the clin­ic

4 years ago
Financing
AI

In Cure­Vac's fail­ure, a pos­si­ble ver­dict on the past (and fu­ture) of mR­NA vac­cines

4 years ago
R&D
In Focus

Am­gen bel­lies back up to the M&A ta­ble for an­oth­er biotech buy­out, this time with a $2.5B deal for an an­ti­body play­er ...

4 years ago
Deals

Google-backed Cal­i­co dou­bles down on an­ti-ag­ing R&D pact with Ab­b­Vie as part­ners ante up $1B, start to de­tail drug ...

4 years ago
Deals
R&D

Look­ing to repli­cate Covid-19 suc­cess in neu­ro, BioN­Tech back­ers bet on AC Im­mune and its new­ly-ac­quired Parkin­son's ...

4 years ago
Financing
Deals

Mer­ck­'s wom­en's health spin­out snags mid-stage can­di­date for preterm birth; Keytru­da nails down TNBC ap­proval af­ter ...

4 years ago
News Briefing

Can­del gets busy IPO week mov­ing with down­sized raise as Ra­jiv Shuk­la's third SPAC goes pub­lic

4 years ago
Financing

Pan­el of neu­ro­science ex­perts lays out the com­pli­ca­tions with us­ing Bio­gen's new Alzheimer's drug

4 years ago
R&D
Pharma

Covid-19 roundup: Till­man Gern­gross inks deal to bring an­ti­body can­di­date to In­dia; At FDA's re­quest, mR­NA vac­cine ...

4 years ago
Coronavirus

Take­da flesh­es out CNS pact with pep­tide drug­mak­er, set­ting aside $3.5B in fu­ture mile­stones

4 years ago
Deals
R&D

Re­gen­eron's lat­est ge­net­ics dis­cov­ery hooks As­traZeneca — now all-in on de­vel­op­ing small mol­e­cules for obe­si­ty

4 years ago
R&D

Wav­ing off re­cent PhII flop, Bio­gen trum­pets ear­ly pos­i­tive Alzheimer's da­ta for an­ti-tau an­ti­sense

4 years ago
R&D

Bris­tol My­ers Squibb catch­es the SHP2 wave in a new col­lab­o­ra­tion deal with Bridge­Bio

4 years ago
Deals

Busi­ness­es and schools can man­date the use of Covid-19 vac­cines un­der EUAs, DOJ says

4 years ago
FDA+
Coronavirus

BioN­Tech is spear­head­ing an mR­NA vac­cine de­vel­op­ment pro­gram for malar­ia, with a tech trans­fer planned for Africa

4 years ago
R&D
Manufacturing

How one start­up fore­told the neu­ro­science re­nais­sance af­ter '50 years of shit­show'

4 years ago
R&D
In Focus
First page Previous page 660661662663664665666 Next page Last page
A service from the Financial Times